MedPath

Prospective study for clarification of mechanisms of acquired resistance for afatinib using plasma samples

Not Applicable
Conditions
on-small cell lung cancer
Registration Number
JPRN-UMIN000026108
Lead Sponsor
Saga Univ,Clinical research center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
29
Inclusion Criteria

Not provided

Exclusion Criteria

1. Previously treated with an EGFR TKI. 2. Previously treated with an immune checkpoint inhibitor. 3. Patients who, in the opinion of the attending physician, are inappropriate for the study .

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath